Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours.

MLA

Dretzke, J., et al. “Imatinib as Adjuvant Treatment Following Resection of KIT-Positive Gastrointestinal Stromal Tumours.” Health Technology Assessment (Winchester, England), vol. 14, no. Suppl. 2, Oct. 2010, pp. 63–70. EBSCOhost, https://doi.org/10.3310/hta14suppl2/09.

APA

Dretzke, J., Round, J., Connock, M., Tubeuf, S., Pennant, M., Fry-Smith, A., Hulme, C., McCabe, C., & Meads, C. (2010). Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours. Health Technology Assessment (Winchester, England), 14(Suppl. 2), 63–70. https://doi.org/10.3310/hta14suppl2/09

Chicago

Dretzke, J, J Round, M Connock, S Tubeuf, M Pennant, A Fry-Smith, C Hulme, C McCabe, and C Meads. 2010. “Imatinib as Adjuvant Treatment Following Resection of KIT-Positive Gastrointestinal Stromal Tumours.” Health Technology Assessment (Winchester, England) 14 (Suppl. 2): 63–70. doi:10.3310/hta14suppl2/09.